cyt004-melqbg10
Vaccineexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 23, 2006 (NCT00306566)
Timeline
Indications
Studied for
Mechanism of action
- Melanoma cellsImmunity, active
immunity, active - melanoma cells
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cyt004-melqbg10
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00651703 | Phase 2 | Apr 1, 2008 | Cytos Biotechnology AG |
| NCT00306514 | Phase 1/Phase 2 (Phase 2) | Mar 23, 2006 | Cytos Biotechnology AG, Humboldt University |
| NCT00306553 | Phase 2 | Mar 23, 2006 | Cytos Biotechnology AG, University of Zurich |
| NCT00306566 | Phase 1/Phase 2 (Phase 2) | Mar 23, 2006 | Centre Pluridisciplinaire d'Oncologie & LICR, CHUV, Cytos Biotechnology AG |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cytos Biotechnology AG | For profit | 4 | 4 | 1 | 2006 |
| Centre Pluridisciplinaire d'Oncologie & LICR, CHUV | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Humboldt University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Zurich | Academic/Hospital | 1 | 0 | 1 | 2006 |
4 organizations
Page 1 / 1